The non-inferiority of the sorafenib (So) and pazopanib (Pa) sequence was not demonstrated compared to pazopanib-sorafenib in patients with metastatic renal cell carcinoma (mRCC).
First-line treatment failed to improve progression-free survival among women of European descent with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC).
First-line nivolumab plus radiotherapy (RT) with or without temozolomide was tolerated by patients with glioblastoma.
Surgical resection of soft tissue or visceral sarcoma conducted at an expert center resulted in substantially better outcomes compared with nonexpert centers.
Binimetinib a BRAF inhibitor, improved objective response rate (ORR) and progression-free survival (PFS) among patients with BRAF-mutant melanoma.
Adoptive cellular immunotherapy has not been widely used for cancer treatment.
Immune checkpoint inhibition may improve the efficacy of vaccine-induced T cells in incurable HPV genotype 16-positive cancer.
